SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 9/26/2016 4:28:57 PM - Followers: 705 - Board type: Free - Posts Today: 69

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

Upcoming Milestones:
 


Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Current Report Filing (8-k) 09/15/2016 08:01:38 AM
CTIX News: Current Report Filing (8-k) 09/13/2016 08:01:27 AM
CTIX News: Annual Report (10-k) 09/13/2016 06:04:52 AM
CTIX News: Insider Financial Publishes New Research On Three Promising Biotechs 07/16/2016 08:00:00 AM
CTIX News: Securities Registration: Employee Benefit Plan (s-8) 07/15/2016 04:52:11 PM
PostSubject
#159155  Sticky Note Chart showing 2016 Milestones KarinCA 09/13/16 02:49:10 PM
#158037  Sticky Note 9-1-16 New Cellceutix Report Out. Worth a read imo. TheHound 09/01/16 08:36:02 AM
#156616  Sticky Note Interview With New Cellceutix President Dr A Bertolino BigKahuna 08/11/16 11:49:13 PM
#156603  Sticky Note CTIX Interviews, Potential Catalysts and Past Milestones sox040713 08/11/16 06:13:05 PM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#160287   What part of his post did you like eventhelosers 09/26/16 04:28:57 PM
#160286   good post imo. thanks noretreat 09/26/16 04:24:05 PM
#160285   LOL - I'll take that bet NotRichYet2 09/26/16 04:08:13 PM
#160284   To answer your question: If the price noretreat 09/26/16 04:06:27 PM
#160283   Funding the P3 is the 800lb gorilla in noretreat 09/26/16 04:00:44 PM
#160282   Right, maybe if they give 600 mg, they KMBJN 09/26/16 03:58:47 PM
#160281   Thanks Det...interesting ! wild4ctix 09/26/16 03:40:00 PM
#160280   Pfizer decides against split-up; more deals seem likely. Detonate 09/26/16 03:23:17 PM
#160279   Me too with fidelity , no problem. youssef 09/26/16 03:08:37 PM
#160278   Get a new broker. That's ridiculous and KarinCA 09/26/16 02:27:46 PM
#160277   i have and was denied. i thought the TheHound 09/26/16 02:21:51 PM
#160276   Call in and specifically ask for online permissions. KarinCA 09/26/16 02:18:09 PM
#160275   noretreat....question for you.(...and everyone) 123tom 09/26/16 02:05:36 PM
#160274   I wonder if P is going to have vip1999 09/26/16 02:04:15 PM
#160273   My pleasure Mich I'm actually heading back to luxe 09/26/16 02:04:07 PM
#160272   Remember JC lost a few followers along the luxe 09/26/16 01:59:23 PM
#160271   And your blaming me for the shitty trading luxe 09/26/16 01:55:02 PM
#160270   $CTIX - NEW TRIAL DATA JUST RELEASED. Prurisol: A TheHound 09/26/16 12:39:35 PM
#160267   With Fidelity before I could trade penny stocks Barron4664 09/26/16 12:15:27 PM
#160266   YES - Have only been POSTING on CTIX NotRichYet2 09/26/16 12:00:50 PM
#160264   Never had a problem trading In and out Blue Fin 09/26/16 11:38:12 AM
#160263   Perhaps this is a restriction with your broker frrol 09/26/16 11:24:44 AM
#160262   George is giving his OPINION on the information NotRichYet2 09/26/16 11:11:28 AM
#160261   it does suck. free though :-) TheHound 09/26/16 11:07:52 AM
#160260   The issue is some brokers won't or can't TheHound 09/26/16 11:06:03 AM
#160259   That doesn't appear to be a universal rule. loanranger 09/26/16 11:05:35 AM
#160258   Thanks for that observation but that's Max's line. Jhawker 09/26/16 11:04:55 AM
#160257   wow that sucks. get etrade, they will vip1999 09/26/16 11:02:26 AM
#160256   Volume today is horrendous Go CTIX tombrady12nh 09/26/16 11:02:07 AM
#160255   you can not use market orders on OTC vip1999 09/26/16 10:59:08 AM
#160254   No problem trading CTIX on Fidelity online. Currently Astavakra 09/26/16 10:55:59 AM
#160253   Scottrade: "Unable to enter order because orders for Bulletin loanranger 09/26/16 10:53:34 AM
#160252   I asked if I could buy with a xoc 09/26/16 10:36:38 AM
#160251   i can't buy online either - never have TheHound 09/26/16 10:34:10 AM
#160250   I cannot buy in my retirement brokerage account xoc 09/26/16 10:29:43 AM
#160249   Predicting trial results. Really? frrol 09/26/16 10:28:39 AM
#160248   MM games can cause some frustration BUT depending NotRichYet2 09/26/16 10:27:33 AM
#160247   Prurisol to provide "clear" or "nearly clear" skin 58nout 09/26/16 10:19:48 AM
#160246   I can't place a trade because of this xoc 09/26/16 10:18:09 AM
#160245   runninggirl2016 I should clarify. I should have said: georgejjl 09/26/16 10:15:14 AM
#160244   George over 75% and Prurisol is the blockbuster runninggirl2016 09/26/16 10:10:03 AM
#160243   MM games. They only show what they want too. NotRichYet2 09/26/16 10:07:04 AM
#160241   Obv they can do a next study including To infinity and beyond! 09/26/16 10:05:26 AM
#160240   WHY??? When the right news comes out the NotRichYet2 09/26/16 10:04:44 AM
#160238   Why is there no body or ask posted xoc 09/26/16 10:01:55 AM
#160237   Expect about 92% of the subjects in the georgejjl 09/26/16 09:59:59 AM
#160236   Need a weekly close over 1.42 MXAMDUD 09/26/16 09:39:01 AM
#160235   IL-20 reduced by 69% and 87% after treatment georgejjl 09/26/16 09:36:06 AM
#160234   Now that's a QUOTE that should stay as NotRichYet2 09/26/16 09:29:29 AM
#160232   Prurisol may be a new therapeutic strategy for asthma georgejjl 09/26/16 09:12:15 AM
PostSubject